People with inoperable anal cancers who received carboplatin-paclitaxel had fewer complications and lived longer than those who received other chemotherapy, which was prescribed more often..

The results of an international study published by the Journal of Clinical Oncology indicate that carboplatin-paclitaxel has become the standard treatment for cancer of the anal canal, a rare disease that accounts for less than 3% of all malignant tumors of the gastrointestinal tract. An InterAAct study compared carboplatin paclitaxel with cisplatin plus 5-fluoracil (5FU).

“InterAAct study identifies carboplatin-paclitaxel as the optimal first-line chemotherapy regimen for inoperable anal cancer. Carboplatin-paclitaxel has been associated with less toxicity and a tendency to improve survival, which suggests that it should become the standard of care for these patients and the basis for future trials of the third phase, ”said Katie Eng, MD, leading American researcher, David X. Johnson Department of Surgical and Medical Oncology at Vanderbilt University and co-director of the Gastrointestinal Cancer Research Program at the Vanderbilt-Ingram Cancer Center.

The overall survival of patients included in the clinical study on carboplatin-paclitaxel was 20 months compared with 12.3 months for patients on cisplatin-5fu arm. Carboplatin-paclitaxel was associated with significantly fewer side effects (36%) compared with cisplatin-5FU (62%).

The study included 91 patients from the United States, Australia, Germany, Norway and the United Kingdom from December 2013 to November 2017.. The International Rare Cancer Initiative has formed a working group on anal cancer to develop and conduct research to provide new treatment strategies for metastatic anal cancer patients. According to statistics, patients with inoperable cancer of the anal canal have a five-year survival rate of about 30%.

Paclitaxel was first documented as a treatment for advanced anal cancer in 2011 and was later combined with carboplatin..

A 69% response rate led some clinicians to prescribe it as a first-line treatment, but the cisplatin-5FU regimen was accepted internationally..

The International Rare Cancer Initiative, the Anal Cancer Working Group, the National Cancer Institute, and the ECOG-ACRIN Cancer Research Group initiated a clinical trial comparing two chemotherapies to provide clinicians and clinical researchers with better guidance on the future development of clinical trials..

med-heal. ru.